OBJECTIVE: Nearly 20%-29% of patients with colorectal cancer (CRC) succumb to liver or lung metastasis and there is a dire need for novel targets to improve the survival of patients with metastasis. The long isoform of the Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1-L or CC1-L) is a key regulator of immune surveillance in primary CRC, but its role in metastasis remains largely unexplored. We have examined how CC1-L expression impacts on colon cancer liver metastasis. DESIGN: Murine MC38 transfected with CC1-L were evaluated in vitro for proliferation, migration and invasion, and for in vivo experimental liver metastasis. Using shRNA silencing or pharmacological inhibition, we delineated the role in liver metastasis of Chemokine (C-C motif) Ligand 2 (CCL2) and Signal Transducer and Activator of Transcription 3 (STAT3) downstream of CC1-L. We further assessed the clinical relevance of these findings in a cohort of patients with CRC. RESULTS: MC38-CC1-L-expressing cells exhibited significantly reduced in vivo liver metastasis and displayed decreased CCL2 chemokine secretion and reduced STAT3 activity. Down-modulation of CCL2 expression and pharmacological inhibition of STAT3 activity in MC38 cells led to reduced cell invasion capacity and decreased liver metastasis. The clinical relevance of our findings is illustrated by the fact that high CC1 expression in patients with CRC combined with some inflammation-regulated and STAT3-regulated genes correlate with improved 10-year survival. CONCLUSIONS: CC1-L regulates inflammation and STAT3 signalling and contributes to the maintenance of a less-invasive CRC metastatic phenotype of poorly differentiated carcinomas. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVE: Nearly 20%-29% of patients with colorectal cancer (CRC) succumb to liver or lung metastasis and there is a dire need for novel targets to improve the survival of patients with metastasis. The long isoform of the Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1-L or CC1-L) is a key regulator of immune surveillance in primary CRC, but its role in metastasis remains largely unexplored. We have examined how CC1-L expression impacts on colon cancer liver metastasis. DESIGN:Murine MC38 transfected with CC1-L were evaluated in vitro for proliferation, migration and invasion, and for in vivo experimental liver metastasis. Using shRNA silencing or pharmacological inhibition, we delineated the role in liver metastasis of Chemokine (C-C motif) Ligand 2 (CCL2) and Signal Transducer and Activator of Transcription 3 (STAT3) downstream of CC1-L. We further assessed the clinical relevance of these findings in a cohort of patients with CRC. RESULTS: MC38-CC1-L-expressing cells exhibited significantly reduced in vivo liver metastasis and displayed decreased CCL2 chemokine secretion and reduced STAT3 activity. Down-modulation of CCL2 expression and pharmacological inhibition of STAT3 activity in MC38 cells led to reduced cell invasion capacity and decreased liver metastasis. The clinical relevance of our findings is illustrated by the fact that high CC1 expression in patients with CRC combined with some inflammation-regulated and STAT3-regulated genes correlate with improved 10-year survival. CONCLUSIONS:CC1-L regulates inflammation and STAT3 signalling and contributes to the maintenance of a less-invasive CRC metastatic phenotype of poorly differentiated carcinomas. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Xiaolei Zhang; Peibin Yue; Brent D G Page; Tianshu Li; Wei Zhao; Andrew T Namanja; David Paladino; Jihe Zhao; Yuan Chen; Patrick T Gunning; James Turkson Journal: Proc Natl Acad Sci U S A Date: 2012-05-23 Impact factor: 11.205
Authors: D Gerstel; F Wegwitz; K Jannasch; P Ludewig; K Scheike; F Alves; N Beauchemin; W Deppert; C Wagener; A K Horst Journal: Oncogene Date: 2011-05-02 Impact factor: 9.867
Authors: Monika Julia Wolf; Alexandra Hoos; Judith Bauer; Steffen Boettcher; Markus Knust; Achim Weber; Nicole Simonavicius; Christoph Schneider; Matthias Lang; Michael Stürzl; Roland S Croner; Andreas Konrad; Markus G Manz; Holger Moch; Adriano Aguzzi; Geert van Loo; Manolis Pasparakis; Marco Prinz; Lubor Borsig; Mathias Heikenwalder Journal: Cancer Cell Date: 2012-07-10 Impact factor: 31.743
Authors: Roni F Rayes; Phil Vourtzoumis; Marianne Bou Rjeily; Rashmi Seth; France Bourdeau; Betty Giannias; Julie Berube; Yu-Hwa Huang; Simon Rousseau; Sophie Camilleri-Broet; Richard S Blumberg; Nicole Beauchemin; Sara Najmeh; Jonathan Cools-Lartigue; Jonathan D Spicer; Lorenzo E Ferri Journal: J Immunol Date: 2020-03-13 Impact factor: 5.422
Authors: Jehnan Liu; Harrison T Muturi; Saja S Khuder; Raghd Abu Helal; Hilda E Ghadieh; Sadeesh K Ramakrishnan; Meenakshi K Kaw; Sumona Ghosh Lester; Ahmed Al-Khudhair; Philip B Conran; Khew-Voon Chin; Cara Gatto-Weis; Sonia M Najjar Journal: Metabolism Date: 2020-03-21 Impact factor: 8.694
Authors: Azadeh Arabzadeh; Kevin McGregor; Valérie Breton; Lauren Van Der Kraak; Uri David Akavia; Celia M T Greenwood; Nicole Beauchemin Journal: Oncotarget Date: 2017-11-01
Authors: Matthew Dankner; Scott D Gray-Owen; Yu-Hwa Huang; Richard S Blumberg; Nicole Beauchemin Journal: Oncoimmunology Date: 2017-05-16 Impact factor: 8.110
Authors: Thiviya Jeyakumar; Nassima Fodil; Lauren Van Der Kraak; Charles Meunier; Romain Cayrol; Kevin McGregor; David Langlais; Celia M T Greenwood; Nicole Beauchemin; Philippe Gros Journal: Sci Rep Date: 2019-12-11 Impact factor: 4.379